# Progress Note 06 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Voltaire (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-EN002-SYN
- Date: 2026-05-06
- Fictional facility: St. Posthumous Health Center
- Fictional author: Honorine Delacroix-Mensah, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Two-week review during weekly radiotherapy. **S**

## History of present illness

Voltaire returns two weeks after starting the pain plan. He had the first radiotherapy fraction a week ago and the second this morning. Since the first fraction he has passed urine more often, about every two hours by day and twice at night, with mild burning, but the stream is steady and there have been no clots; the urine is pale pink on some days. He takes acetaminophen three times a day and has used eight half tablets of oxycodone in fourteen days, mostly in the evening, with good relief and no drowsiness, confusion, or falls; seven tablets remain in the locked box, and he has taken nothing else for pain or sleep. His bowels open daily on polyethylene glycol and senna. The palliative care team visited him at home last week. The physical therapist from the wellness visit has not yet come. He has lost 0.5 kg and drinks the supplement once a day. He wrote every morning this week. **S**

| Element | Detail |
|---|---|
| Radiotherapy | Fractions 1 and 2 of 6 given; mild frequency and burning |
| Voiding | Steady stream; nocturia twice; residual 120 mL |
| Pain | 2 of 10 on acetaminophen and about one half tablet of oxycodone a day |
| Opioid safety | Eight half tablets used in fourteen days; no sedation, falls, or other sedatives |
| Weight | 53.0 kg, down 0.5 kg |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | More tired on treatment days; weight down 0.5 kg |
| Genitourinary | Positive | Frequency every two hours, nocturia twice, mild burning; pale pink urine on some days; no clots |
| Gastrointestinal | Negative | Bowels open daily; no diarrhea or rectal bleeding |
| Neurological | Negative | No drowsiness, confusion, or falls |
| Psychiatric | Negative | Mood steady; sleeping about five hours |

5 systems reviewed. **S**

## Current medications

- Tamsulosin 0.4 mg oral capsule, one capsule at bedtime **S**
- Polyethylene glycol 3350, 17 g in a glass of water once daily **S**
- Acetaminophen 500 mg oral tablet, two tablets by mouth three times daily (3 g a day) **S**
- Oxycodone 5 mg oral tablet, one half tablet (2.5 mg) by mouth every 6 hours if needed for bladder pain not relieved by acetaminophen, no more than three doses a day; 15 tablets dispensed **S**
- Sennosides 8.6 mg oral tablet, two tablets at bedtime while taking oxycodone **S**
- Naloxone 4 mg nasal spray, one spray in one nostril for suspected opioid overdose; call 911; may repeat in 2 to 3 minutes in the other nostril **S**

## Allergies

- No known allergy **S**

## Objective

BP 122/68 mmHg; pulse 80 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 96% on room air; weight 53 kg; BMI 18.3 kg/m². All vital signs are synthetic.

Hemoglobin: 10.8 g/dL (low); White blood cells: 6.9 10*3/uL; Platelets: 231 10*3/uL; Potassium: 4.4 mmol/L; Creatinine: 1.2 mg/dL; eGFR: 60 mL/min/1.73 m²; Post-void residual (bladder scan): 120 mL (high); IPSS: 15; Pain score: 2. All results are synthetic.

## Change since baseline

- Hemoglobin: 11.6 g/dL (low) at baseline, 10.8 g/dL (low) at this visit **S**
- White blood cells: 7.8 10*3/uL at baseline, 6.9 10*3/uL at this visit **S**
- Platelets: 268 10*3/uL at baseline, 231 10*3/uL at this visit **S**
- Potassium: 5 mmol/L at baseline, 4.4 mmol/L at this visit **S**
- Creatinine: 1.68 mg/dL (high) at baseline, 1.2 mg/dL at this visit **S**
- eGFR: 40 mL/min/1.73 m² (low) at baseline, 60 mL/min/1.73 m² at this visit **S**
- Post-void residual (bladder scan): 460 mL (high) at baseline, 120 mL (high) at this visit **S**
- IPSS: 22 at baseline, 15 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Thin, alert, and lively; not drowsy; pupils normal size |
| Cardiovascular | Blood pressure 122/68 mmHg; heart rate 80, regular |
| Respiratory | Respiratory rate 16; oxygen saturation 96 percent |
| Abdomen | Soft; mild suprapubic tenderness; bladder not palpable |
| Skin | No skin reaction over the pelvis |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Squamous cell carcinoma of the bladder, on weekly radiotherapy** (C67.4). Two of six fractions given, with grade 1 radiation cystitis (frequency, nocturia, mild burning) and no grade 2 or higher effects. Bleeding is controlled. Hemoglobin 10.8 g/dL, white count 6.9, platelets 231, and creatinine 1.20 mg/dL (eGFR 60) are stable. The pain plan works: pain 2 of 10 with about one half tablet of oxycodone a day, without sedation or constipation. **S**
   - Continue weekly radiotherapy to six fractions.
   - Continue acetaminophen; oxycodone 2.5 mg as needed, the same limits; no new prescription needed yet.
   - The palliative care team will keep visiting at home.
2. **Chronic urinary retention** (R33.8). Post-void residual 120 mL, stable; IPSS 15 with radiation frequency. **S**
   - Continue tamsulosin; bladder scan at the next visit.
3. **Chronic constipation** (K59.09). Controlled on polyethylene glycol and senna while on oxycodone. **S**
   - No change.
4. **Benign prostatic hyperplasia** (N40.1). Symptoms explained by radiation and the enlarged prostate; no dizziness on tamsulosin. **S**
   - No change.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Blood count and kidney function during radiotherapy | At each visit during treatment | Completed today | Hemoglobin 10.8 g/dL, white count 6.9, platelets 231; creatinine 1.20 mg/dL (eGFR 60), potassium 4.4 mmol/L; stable |
| Examination | Post-void residual | At baseline when retention is suspected, after a trial without catheter, and when symptoms change | Completed today | 120 mL, stable |
| Survey | IPSS | Baseline and at every follow-up visit (CMID BPH) | Completed today | 15, moderate; frequency from radiotherapy |
| Survey | Pain intensity (0 to 10) | At every visit with cancer pain | Completed today | 2 of 10 |
| Examination | Radiation toxicity (bladder and bowel) | Weekly during radiotherapy | Completed today | Grade 1 cystitis; no bowel toxicity or skin reaction |
| Medication safety | Opioid follow-up: benefit, sedation, falls, constipation, use against the plan, prescription monitoring program, and naloxone at home | Within 1 to 4 weeks of starting, then at least every three months | Completed today | Eight half tablets in fourteen days, as prescribed; no sedation or falls; bowels regular; prescription monitoring program shows only this prescription; naloxone at home and his assistant trained |
| Referral | Home physical therapy for strength and balance | Within one to two weeks of the falls assessment | Deferred | Missed: home physical therapy ordered at the wellness visit has not started because the agency had no therapist free. No harm: he has had no falls. Corrective action: the clinic arranged a second agency, which will visit this week, and gave him a printed set of chair exercises in the meantime |
| Self-management | Weight and nutrition | At every visit while weight is falling | Completed today | 53.0 kg, down 0.5 kg; supplement once a day; asked to take it twice |
| Imaging | Bladder cancer surveillance schedule (cystoscopy and cytology for NMIBC; CT every 6 to 12 months after cystectomy) | Applies after NMIBC treatment or cystectomy | Not indicated | Neither applies: he has muscle-invasive disease treated with palliative-intent radiotherapy, so response is judged by symptoms, with cystoscopy or CT only if they would change care |

## Goal progress

- Find the cause of the bleeding within three weeks. Outcome by 2026-04-22: CT urography in two days, cystoscopy in one week, resection in nine days; pathology reviewed at sixteen days. **S**
- Relieve the retention and recover kidney function. Outcome by 2026-04-22: Creatinine 1.68 to 1.22 mg/dL; voiding after the trial without catheter with a residual of 140 mL. **S**
- Treatment that controls bleeding and local symptoms while keeping him at home and writing. In progress; target 2026-05-27. **S**
- Pain at or below 3 of 10 without sedation, falls, or constipation. In progress; target 2026-05-27. **S**
- A written plan for future care, with a named health care agent. Outcome by 2026-04-28: Health care agent named and a portable medical order completed at the wellness visit. **S**

## Guideline basis

- Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO Guideline (2017; Amended 2020, 2024) (2024), American Urological Association
- NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer, Version 3.2026 (including non-urothelial histologies) (2026), National Comprehensive Cancer Network
- EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer (2026), European Association of Urology
- Clinical Outcomes of Image Guided Adaptive Hypofractionated Weekly Radiation Therapy for Bladder Cancer in Patients Unsuitable for Radical Treatment (Hafeez S, et al.) (2017), International Journal of Radiation Oncology, Biology, Physics
- Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia (BPH): AUA Guideline Amendment 2023 (2023), American Urological Association
- CDC Clinical Practice Guideline for Prescribing Opioids for Pain, United States, 2022 (2022), Centers for Disease Control and Prevention
- American Geriatrics Society 2023 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults (2023), American Geriatrics Society
- Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology (2018), American Society of Clinical Oncology
- CMID: Clinical Monitoring Intelligence Database, urologic cancer and benign prostatic hyperplasia monographs (2026), Aether Forge
- Falls Prevention in Community-Dwelling Older Adults: Interventions (2024), U.S. Preventive Services Task Force

## Follow-up

- Chronic-care review in two weeks, after the fourth fraction; call for clots, a weak stream or inability to pass urine, fever, or pain not controlled. **S**

